TGFB1 and pulmonary fibrosis: MSC therapy in BPF models in rodents showed reductions in lung collagen deposition (22, 30–43), lung fibrosis (22, 32, 34, 35, 37, 38), TGF-β levels (22, 30–36, 38–41) and total and/or neutrophil cell count in the bronchoalveolar lavage fluid (BALF) (34, 36, 37, 39) and improved 14-day survival (22, 34, 36) after bleomycin administration.